HomeCompareVAIAF vs PFE

VAIAF vs PFE: Dividend Comparison 2026

VAIAF yields 1.44% · PFE yields 6.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 PFE wins by $7.4K in total portfolio value· pulled ahead in Year 10
10 years
VAIAF
VAIAF
● Live price
1.44%
Share price
$51.35
Annual div
$0.74
5Y div CAGR
39.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$42.2K
Annual income
$7,079.86
Full VAIAF calculator →
PFE
Pfizer Inc.
● Live price
6.13%
Share price
$28.08
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.6K
Annual income
$26,258.71
Full PFE calculator →

Portfolio growth — VAIAF vs PFE

📍 PFE pulled ahead of the other in Year 10

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodVAIAFPFE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, VAIAF + PFE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
VAIAF pays
PFE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

VAIAF
Annual income on $10K today (after 15% tax)
$122.59/yr
After 10yr DRIP, annual income (after tax)
$6,017.88/yr
PFE
Annual income on $10K today (after 15% tax)
$520.66/yr
After 10yr DRIP, annual income (after tax)
$22,319.90/yr
At 15% tax rate, PFE beats the other by $16,302.02/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of VAIAF + PFE for your $10,000?

VAIAF: 50%PFE: 50%
100% PFE50/50100% VAIAF
Portfolio after 10yr
$45.9K
Annual income
$16,669.29/yr
Blended yield
36.34%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PFE right now

VAIAF
No analyst data
Altman Z
6.7
Piotroski
6/9
PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-2.1% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

VAIAF buys
0
PFE buys
0
No recent congressional trades found for VAIAF or PFE in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricVAIAFPFE
Forward yield1.44%6.13%
Annual dividend / share$0.74$1.72
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR39.3%13.2%
Portfolio after 10y$42.2K$49.6K
Annual income after 10y$7,079.86$26,258.71
Total dividends collected$19.7K$58.3K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: VAIAF vs PFE ($10,000, DRIP)

YearVAIAF PortfolioVAIAF Income/yrPFE PortfolioPFE Income/yrGap
1$10,901$200.91$9,153$693.39+$1.7KVAIAF
2$11,949$285.12$8,593$849.25+$3.4KVAIAF
3$13,192$406.88$8,336$1,066.78+$4.9KVAIAF
4$14,701$584.82$8,437$1,384.80+$6.3KVAIAF
5$16,578$848.40$9,013$1,875.40+$7.6KVAIAF
6$18,984$1,245.57$10,306$2,680.72+$8.7KVAIAF
7$22,170$1,856.91$12,820$4,101.38+$9.3KVAIAF
8$26,545$2,823.13$17,673$6,826.70+$8.9KVAIAF
9$32,804$4,400.64$27,543$12,591.86+$5.3KVAIAF
10← crossover$42,180$7,079.86$49,560$26,258.71$7.4KPFE

VAIAF vs PFE: Complete Analysis 2026

VAIAFStock

Vaisala Oyj engages in the weather and environmental, and industrial measurement business serving weather related and industrial markets. The company's products include industrial measurement systems, such as HVAC and indoor air meters, industrial transmitters, power transformer monitoring systems, probes and OEM modules, handheld meters, in-line process refractometers, biogas monitoring systems, liquid measurement systems, and viewLinc continuous monitoring systems. It also provides weather and environmental solutions, such as automatic weather stations, radiosondes and sounding systems, weather and environmental sensors, weather radars, wind lidars, visibility and present weather sensors, ceilometers, lightning sensors, air quality sensors, and road state sensors, as well as pressure, temperature, and humidity sensors; and operates an online store. In addition, the company offers maintenance, calibration and repair, and modernization services, as well as extended warranties and data-based solutions. Vaisala Oyj serves various industrial customers, including data centers, chemicals and allied products, fuel cells, power transformers, semiconductors, automotive, cleanrooms, HVAC and indoor air, warehouses, battery manufacturing, compressed air, life sciences and pharmaceutical, sugar, sweeteners, biogas, and research facilities and metrology; pulp, paper, and wood; food, beverages, and agriculture; and oil and gas refineries, and petrochemicals. It also serves weather-dependent markets mainly meteorology, ground transportation, aviation, maritime, renewable and wind energy, and urban weather and environment. The company has operations in Europe, the Middle East, Africa, North and South Americas, and the Asia Pacific. Vaisala Oyj was founded in 1936 and is headquartered in Vantaa, Finland.

Full VAIAF Calculator →

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →
📬

Get this VAIAF vs PFE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

VAIAF vs SCHDVAIAF vs JEPIVAIAF vs OVAIAF vs KOVAIAF vs MAINVAIAF vs JNJVAIAF vs MRKVAIAF vs ABBV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.